Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6819089 | 1.00 | TACR1 (0.43) | TACR1PDE2AIDO1TDO2CASR | |
| SCHEMBL336049 | 0.87 | TACR1 (0.51) | TACR1PDE2AIDO1TDO2HTR2A | |
| SCHEMBL1728680 | 0.87 | TACR1 (0.51) | TACR1PDE2AIDO1TDO2HTR2A | |
| SCHEMBL1492761 | 0.87 | TACR1 (0.51) | TACR1PDE2AIDO1TDO2HTR2A | |
| SCHEMBL6917133 | 0.87 | TACR1 (0.51) | TACR1PDE2AIDO1TDO2HTR2A | |
| SCHEMBL7939177 | 0.87 | TACR1 (0.51) | TACR1PDE2AIDO1TDO2HTR2A | |
| Hydrochloric Acid SCHEMBL7170075 | 0.85 | TACR1 (0.50) | TACR1PDE2AIDO1TDO2HTR2A | |
| Hydrochloric Acid SCHEMBL4471353 | 0.85 | TACR1 (0.50) | TACR1PDE2AIDO1TDO2HTR2A | |
| Methane SCHEMBL4258949 | 0.85 | TACR1 (0.50) | TACR1PDE2AIDO1TDO2HTR2A | |
| Hydrochloric Acid SCHEMBL17439064 | 0.85 | TACR1 (0.50) | TACR1PDE2AIDO1TDO2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113727758-A | Bicyclic heterocyclic compounds and use thereof | 锐新医药公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | TACR1 16/4885PDE2A 334/4885IDO1 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.